LGND Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of -82.06%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 27.83%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $91.13 which suggests that it could grow by 4.82%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.182, which suggesting that the stock is 18.151% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 91.66x while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 14.92x versus 14.73x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 20.83%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Johnson & Johnson's return on equity of 33.27%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 27.83%. On the other hand Johnson & Johnson has an analysts' consensus of $230.63 which suggests that it could fall by -3.9%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Ligand Pharmaceuticals, Inc. has a beta of 1.182, which suggesting that the stock is 18.151% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.14% to investors and pays a quarterly dividend of $1.30 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is lower than Johnson & Johnson's net income of $5.1B. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 91.66x while Johnson & Johnson's PE ratio is 21.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 14.92x versus 6.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 81.15%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Krystal Biotech, Inc.'s return on equity of 19.91%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 27.83%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $289.10 which suggests that it could grow by 6%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.182, which suggesting that the stock is 18.151% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.493, suggesting its less volatile than the S&P 500 by 50.719%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is higher than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 91.66x while Krystal Biotech, Inc.'s PE ratio is 40.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 14.92x versus 21.81x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 18.06%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Merck & Co., Inc.'s return on equity of 39.63%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 27.83%. On the other hand Merck & Co., Inc. has an analysts' consensus of $121.27 which suggests that it could fall by -0.54%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.182, which suggesting that the stock is 18.151% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.69% to investors and pays a quarterly dividend of $0.85 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 91.66x while Merck & Co., Inc.'s PE ratio is 16.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 14.92x versus 4.70x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.